Evidence map›Paper›PMID 41646262›Full record

ArticleESMO gastrointestinal oncology2025

GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial.

R C Grant, K Duan, R Jackson, W Greenhalf, E Costello-Goldring, P Ghaneh, C Halloran, D Palmer, T Hackert, M Büchler and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

R C GrantWallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
K DuanDivision of Anatomic Pathology, Laboratory Medicine Program, University Health Network, Toronto, Canada.
R JacksonMolecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
W GreenhalfMolecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
E Costello-GoldringMolecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
P GhanehThe Royal Liverpool University Hospital, Liverpool, UK.
C HalloranMolecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
D PalmerMolecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
T HackertDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
M BüchlerDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
S HutchinsonWallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
S RamotarWallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
A DoddWallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
J WilsonOntario Institute for Cancer Research, Toronto, Canada.
F NottaOntario Institute for Cancer Research, Toronto, Canada.
G O'KaneWallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
J KnoxWallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
J NeoptolemosDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
S GallingerWallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
S E FischerDivision of Anatomic Pathology, Laboratory Medicine Program, University Health Network, Toronto, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: No prognostic biomarker is currently used in clinical management of patients with surgically resected pancreatic cancer other than CA-19-9. In this study, we tested the prognostic value of GATA6 measured with immunohistochemistry and digital assistance. Patients and methods: One hundred and ninety-three patients with resected pancreatic ductal adenocarcinoma from the ESPAC-4 trial of adjuvant gemcitabine and capecitabine were included. Two pathologists independently assessed GATA6 protein expression by immunohistochemistry in tissue microarray cores, manually and with digital assistance. Overall survival was compared across GATA6 levels using multivariate Cox proportional hazard regressions, with exploratory analyses evaluating recurrence-free survival and differential treatment effects. Results: Interobserver concordance improved with digitally assisted scoring (kappa 0.72 versus 0.25, Conclusions: GATA6 expression measured by immunohistochemistry with digital assistance was a prognostic biomarker among people with pancreatic adenocarcinoma treated with surgical resection and adjuvant chemotherapy.

Indexed as

biomarkersdigital pathologyGATA6pancreatic cancer

Identifiers

PMID41646262
PMCPMC12836666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.